Sector News

Heads will roll at GlaxoSmithKline, investors say. The question is, whose?

September 23, 2014
Life sciences
China corruption settlement, check. Now GlaxoSmithKline ($GSK) CEO Andrew Witty needs to come to terms with investors. With quarterly sales off and new drugs lagging, shareholders are demanding change at the top–and this time, some are willing to go on the record.
 
Two weeks ago, investors were said to be agitating for a board shake-up. The photogenic reason? Glaxo’s tarnished image, what with bribery probes around the world. But GSK’s lousy second-quarter numbers probably play a bigger role. They said they’d like to banish Chairman Christopher Gent, already scheduled to step down at the end of next year, as a way to jump-start change.
 
Either that, or toss out Witty.
 
Now, with the China corruption probe wrapped up–and an agreed $500 million fine, less than some had feared–the focus is squarely on the numbers. Namely the lack of profit growth, the slump in Advair sales, and potential pressure on GSK’s dividend.
 
“A new chairman must be overdue,” one “top-50” shareholder told Reuters. “A new chairman could potentially kick-start this change process,” Goldman Sachs analysts told investors in a note Monday.
 
As Reuters notes, booting Gent early is seen as a compromise to save Witty’s job. Another idea? Focus on the U.S., one institutional investor suggests. After all, the U.S. leadership has let Glaxo’s all-important respiratory drug Advair shrink to competition from AstraZeneca’s ($AZN) Symbicort. And their launches of Advair follow-ups Breo and Anoro haven’t performed up to expectations.
 
“I think GSK is a buy when the CEO of that business goes,” John Bennett of Henderson Global Investors told the news service.
 
Goldman disagrees, at least somewhat; the firm’s analysts marked GSK up to “buy” from “neutral” Monday. They’re anticipating some kind of overhaul, though. Summing up the chatter from shareholders and market-watchers, Goldman put it like this: “We believe that status-quo at GSK is unlikely to continue for long.” Indeed.
 
By Tracy Staton
 

comments closed

Related News

October 10, 2021

Nutraceutical giants’ partnerships inject life back into industry at Vitafoods

Life sciences

Some of industry’s biggest players are joining forces to bring cost-effective yet scientifically backed offerings to the nutraceuticals market. Co-creation is reinvigorating supplement innovation, pairing together companies’ diverse expertise, sales networks and clinical trial investments.

October 10, 2021

Pilot launch complete: GlaxoSmithKline’s malaria shot scores WHO backing for wider rollout in Africa

Life sciences

GlaxoSmithKline has spent many years developing and testing its world-first malaria vaccine, but even after a positive recommendation from European regulators in 2015, the shot still isn’t widely deployed. That’s set to change with the World Health Organization’s (WHO’s) blessing for the vaccine.

October 10, 2021

Henrietta Lacks’ estate sues Thermo Fisher for continued sale of HeLa cells without family consent

Life sciences

A sample of Henrietta Lacks’ tissue was taken from her cervix without her consent while she was undergoing cancer treatment at Johns Hopkins Hospital in 1951. Her cells have subsequently been used to develop the polio vaccine, HPV vaccines and gene-mapping techniques and continue to be sold for research purposes by Thermo Fisher Scientific.

Send this to a friend